<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494583</url>
  </required_header>
  <id_info>
    <org_study_id>3475-062</org_study_id>
    <secondary_id>2015-000972-88</secondary_id>
    <secondary_id>163187</secondary_id>
    <secondary_id>MK-3475-062</secondary_id>
    <secondary_id>KEYNOTE-062</secondary_id>
    <nct_id>NCT02494583</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)</brief_title>
  <official_title>A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with
      advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Participants whose tumors
      express programmed death-ligand 1 (PD-L1) will be randomly assigned to one of the three
      treatment arms of the study: pembrolizumab as monotherapy [pembro mono], pembrolizumab plus
      standard of care (SOC) chemotherapy with cisplatin plus 5-fluorouracil (5-FU) or capecitabine
      [pembro combo], or placebo plus SOC chemotherapy with cisplatin plus 5-fluorouracil (5-FU) or
      capecitabine [SOC].

      The primary study hypotheses are that pembrolizumab in combination with SOC chemotherapy is
      superior to SOC chemotherapy alone in terms of Progression-free Survival (PFS) and Overall
      Survival (OS) in participants with PD-L1 Combined Positive Score (CPS) ≥1, pembrolizumab in
      combination with SOC chemotherapy is superior to SOC chemotherapy alone in terms of OS in
      participants with PD-L1 CPS ≥10, pembrolizumab monotherapy is non-inferior to SOC
      chemotherapy alone in terms of OS in participants with PD-L1 CPS ≥1, and pembrolizumab
      monotherapy is superior to SOC chemotherapy alone in terms of OS in participants with PD-L1
      CPS ≥1 and in participants with PD-L1 CPS ≥10.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As specified by the protocol, primary and secondary efficacy analyses will be evaluated in
      gastric cancer participants with PD-L1 CPS ≥1 (all participants) and PD-L1 CPS ≥10 (OS) by
      comparing the pembro mono arm or pembro combo arm separately to the SOC arm.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2015</start_date>
  <completion_date type="Anticipated">June 7, 2021</completion_date>
  <primary_completion_date type="Actual">March 26, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This study is partially blinded. The participant, study site personnel, and the sponsor will be blinded in the pembrolizumab plus SOC chemotherapy (pembro combo) arm and the placebo plus SOC chemotherapy (SOC) arm, but not in the pembro monotherapy (mono arm) since only one type of study medication will be administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pembro Combo vs SOC: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1 (All Participants)</measure>
    <time_frame>Up to approximately 36 months (through Interim Analysis cut-off date of 26-Sep-2018)</time_frame>
    <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.
Per protocol, PFS in the pembro combo arm was compared to the SOC arm as a pre-specified primary analysis of the Intent-To-Treat (ITT) population. PFS is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pembro Combo vs SOC: Overall Survival (OS) in Participants With PD-L1 CPS ≥1 (All Participants)</measure>
    <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, OS was compared separately between CPS ≥1 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pembro Combo vs SOC: OS in Participants With PD-L1 CPS ≥10</measure>
    <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥10. Per protocol, OS was compared separately between CPS ≥10 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ≥1 (All Participants)</measure>
    <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, OS was compared separately between CPS ≥1 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ≥10</measure>
    <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥10. Per protocol, OS was compared separately between CPS ≥10 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pembro Combo vs SOC: Objective Response Rate (ORR) Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</measure>
    <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
    <description>ORR was defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro combo arm was compared to the SOC arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembro Combo vs SOC: Duration of Response (DOR) Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</measure>
    <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
    <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 based upon BICR, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. DOR is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants) and had CR or PR. Per protocol, DOR was compared separately between CPS ≥1 responders of the pembro mono arm and SOC arm and is presented later in the record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembro Mono vs SOC: ORR Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</measure>
    <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
    <description>ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro mono arm was compared to the SOC arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembro Mono vs SOC: DOR Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</measure>
    <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
    <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 based upon BICR, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. DOR is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants) and had CR or PR. Per protocol, DOR was compared separately between CPS ≥1 responders of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembro Mono vs SOC: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</measure>
    <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
    <description>PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.
Per protocol, PFS in the pembro mono arm was compared to the SOC arm as a pre-specified secondary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembro Mono vs SOC: Change From Baseline to Week 18 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question &quot;How would you rate your overall health during the past week?&quot; (Item 29) and the Quality of Life (QoL) question &quot;How would you rate your overall quality of life during the past week?&quot; (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared between all participants of the pembro mono arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared separately between all participants of the pembro combo arm and SOC arm and is presented later in the record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembro Combo vs SOC: Change From Baseline to Week 18 in the EORTC QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Combined Score</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the GHS question &quot;How would you rate your overall health during the past week?&quot; (Item 29) and the QoL question &quot;How would you rate your overall quality of life during the past week?&quot; (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared between all participants of the pembro combo arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared separately between all participants of the pembro mono arm and SOC arm and is presented earlier in the record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembro Mono vs. SOC: Change From Baseline to Week 18 in EORTC QLQ-Module for Gastric Cancer (STO22) Pain Symptom Subscale Score</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales that assess dysphagia (3 items), dietary restriction (4 items), pain (4 items), upper gastro-esophageal symptoms (3 items), and emotional problems (3 items), and questions on dry mouth, taste, body image, and hair loss. Participant responses to the Pain symptom subscale (Items 34-37) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. Per protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared between the pembro mono arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared separately between the pembro combo arm and SOC arm and is presented later in the record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembro Combo vs. SOC: Change From Baseline to Week 18 in EORTC QLQ-STO22 Pain Symptom Subscale Score</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales that assess dysphagia (3 items), dietary restriction (4 items), pain (4 items), upper gastro-esophageal symptoms (3 items), and emotional problems (3 items), and questions on dry mouth, taste, body image, and hair loss. Participant responses to the Pain symptom subscale (Items 34-37) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. Per protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared between the pembro combo arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared separately between the pembro mono arm and SOC arm and is presented earlier in the record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 31.5 months</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an adverse event. The number of participants who experienced an AE was reported for each arm according to the treatment received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 28.5 months</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an adverse event. The number of participants who discontinued study treatment due to an AE was reported for each arm according to the treatment received.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">763</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab Monotherapy (Pembro Mono)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of each 3-week cycle (Q3W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC Chemotherapy (SOC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).</description>
    <arm_group_label>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</arm_group_label>
    <arm_group_label>Pembrolizumab Monotherapy (Pembro Mono)</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 80 mg/m^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).</description>
    <arm_group_label>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</arm_group_label>
    <arm_group_label>Placebo + SOC Chemotherapy (SOC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU 800 mg/m^2/day IV continuous from Day 1-5 of each 3-week cycle.</description>
    <arm_group_label>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</arm_group_label>
    <arm_group_label>Placebo + SOC Chemotherapy (SOC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.</description>
    <arm_group_label>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</arm_group_label>
    <arm_group_label>Placebo + SOC Chemotherapy (SOC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).</description>
    <arm_group_label>Placebo + SOC Chemotherapy (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale within 3 days prior to first dose of study medication

          -  Has histologically- or cytologically-confirmed diagnosis of locally advanced
             unresectable or metastatic gastric or GEJ adenocarcinoma

          -  Human epidermal growth factor receptor 2- (HER2/neu-) negative and programmed cell
             death ligand 1 (PD-L1)-positive

          -  Has measurable disease

          -  Female participants of childbearing potential must be willing to use adequate
             contraception or be surgically sterile, or abstain from heterosexual activity for the
             course of the study through 120 days after the last dose of study medication

          -  Male participants of childbearing potential should agree to use an adequate method of
             contraception starting with the first dose of study medication through 120 days after
             the last dose of study medication

          -  Adequate organ function

        Exclusion Criteria:

          -  Squamous cell or undifferentiated gastric cancer

          -  Previous therapy for locally advanced, unresectable or metastatic gastric/GEJ cancer.
             Participant may have received prior neoadjuvant or adjuvant therapy as long as it was
             completed at least 6 months prior to randomization

          -  Major surgery, open biopsy or significant traumatic injury within 28 days prior to
             randomization, or anticipation of the need for major surgery during the course of
             study treatment.

          -  Radiotherapy within 14 days of randomization

          -  Known additional malignancy that is progressing or requires active treatment with the
             exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin
             that has undergone potentially curative therapy or in situ cervical cancer

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  Active autoimmune disease that has required systemic treatment in past 2 years

          -  Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in
             dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior the first dose of study medication

          -  History of non-infectious pneumonitis that required steroids or current pneumonitis

          -  Active infection requiring systemic therapy

          -  Pregnant, breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 120 days
             after the last dose of study medication

          -  Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, or anti-PD-L2
             agent

          -  Known history of human immunodeficiency virus (HIV)

          -  Known active Hepatitis B or C

          -  Currently participating in and receiving study therapy or has participated in a study
             of an investigational agent or has used an investigational device within 4 weeks prior
             to the first dose of study medication

          -  Received a live vaccine within 30 days prior to the first dose of study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trial Information</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <results_first_submitted>February 28, 2020</results_first_submitted>
  <results_first_submitted_qc>February 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2020</results_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric carcinoma</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Gastroesophageal junction cancer</keyword>
  <keyword>Gastroesophageal junction carcinoma</keyword>
  <keyword>Programmed Cell Death-1 (PD1, PD-1),</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 2 (PDL2, PD-L2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02494583/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who were programmed death-ligand 1 (PD-L1)-positive (Combined Positive Score [CPS]≥1) and human epidermal growth factor receptor 2 (HER2/neu)-negative were recruited to the study.</recruitment_details>
      <pre_assignment_details>Of 1,787 screened, 763 were randomized 1:1:1 to the pembrolizumab monotherapy (pembro mono) arm, pembrolizumab plus standard of care (SOC) chemotherapy (pembro combo) arm, or placebo plus SOC chemotherapy (SOC) arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
          <description>Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W)</description>
        </group>
        <group group_id="P2">
          <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
          <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-fluorouracil (5-FU) 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
        </group>
        <group group_id="P3">
          <title>Placebo + SOC Chemotherapy (SOC)</title>
          <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="257"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="254">1 participant randomized to the pembro combo arm received pembrolizumab monotherapy by mistake.</participants>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="257"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="189"/>
                <participants group_id="P3" count="201"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing in Study</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
          <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
        </group>
        <group group_id="B2">
          <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
          <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Placebo + SOC Chemotherapy (SOC)</title>
          <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="256"/>
            <count group_id="B2" value="257"/>
            <count group_id="B3" value="250"/>
            <count group_id="B4" value="763"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="11.6"/>
                    <measurement group_id="B2" value="60.9" spread="11.6"/>
                    <measurement group_id="B3" value="60.7" spread="12.7"/>
                    <measurement group_id="B4" value="60.5" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="599"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="485"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Participants were stratified according to geographic region of enrolling site:
Europe (including Israel)/North America/Australia, Asia (including East Asia [South Korea, Hong Kong, Taiwan], South East Asia [Malaysia], Thailand, Singapore, Japan), or Rest of the World (including South America).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe/North America/Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rest of the World</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Status</title>
          <description>Participants were stratified according to gastric cancer disease status as either locally advanced unresectable or metastatic disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Locally advanced</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="235"/>
                    <measurement group_id="B4" value="723"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fluoropyrimidine Treatment</title>
          <description>Participants receiving SOC chemotherapy were stratified according to fluoropyrimidine treatment (5-FU or capecitabine).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>5-FU</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="290"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Capecitabine</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pembro Combo vs SOC: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1 (All Participants)</title>
        <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.
Per protocol, PFS in the pembro combo arm was compared to the SOC arm as a pre-specified primary analysis of the Intent-To-Treat (ITT) population. PFS is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
        <time_frame>Up to approximately 36 months (through Interim Analysis cut-off date of 26-Sep-2018)</time_frame>
        <population>All CPS ≥1 participants in the ITT population randomized to the pembro combo arm and SOC arm were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Combo vs SOC: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1 (All Participants)</title>
          <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.
Per protocol, PFS in the pembro combo arm was compared to the SOC arm as a pre-specified primary analysis of the Intent-To-Treat (ITT) population. PFS is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
          <population>All CPS ≥1 participants in the ITT population randomized to the pembro combo arm and SOC arm were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6.9" lower_limit="5.7" upper_limit="7.3"/>
                    <measurement group_id="O3" value="6.4" lower_limit="5.7" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PFS in CPS ≥1 participants of the pembro combo arm was compared to PFS in CPS ≥1 participants of the SOC arm to address the first primary hypothesis (superiority to SOC). The comparison was based on a Cox regression model with Efron’s method of tie handling with treatment as a covariate with stratification according to geographic region, disease status, and fluoropyrimidine treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03918</p_value>
            <p_value_desc>One-sided p-value based on log-rank test with stratification.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pembro Combo vs SOC: Overall Survival (OS) in Participants With PD-L1 CPS ≥1 (All Participants)</title>
        <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, OS was compared separately between CPS ≥1 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
        <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
        <population>All CPS ≥1 participants in the ITT population randomized to the pembro combo arm and SOC arm were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Combo vs SOC: Overall Survival (OS) in Participants With PD-L1 CPS ≥1 (All Participants)</title>
          <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, OS was compared separately between CPS ≥1 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
          <population>All CPS ≥1 participants in the ITT population randomized to the pembro combo arm and SOC arm were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12.5" lower_limit="10.8" upper_limit="13.9"/>
                    <measurement group_id="O3" value="11.1" lower_limit="9.2" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>OS in CPS ≥1 participants of the pembro combo arm was compared to OS in CPS ≥1 participants of the SOC arm to address the second primary hypothesis (superiority to SOC). The comparison was based on a Cox regression model with Efron’s method of tie handling with treatment as a covariate with stratification according to geographic region, disease status, and Fluoropyrimidine treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04611</p_value>
            <p_value_desc>One-sided p-value based on log-rank test with stratification.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pembro Combo vs SOC: OS in Participants With PD-L1 CPS ≥10</title>
        <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥10. Per protocol, OS was compared separately between CPS ≥10 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
        <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
        <population>All CPS ≥10 participants in the ITT population randomized to the pembro combo arm and SOC arm were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Combo vs SOC: OS in Participants With PD-L1 CPS ≥10</title>
          <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥10. Per protocol, OS was compared separately between CPS ≥10 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
          <population>All CPS ≥10 participants in the ITT population randomized to the pembro combo arm and SOC arm were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12.3" lower_limit="9.5" upper_limit="14.8"/>
                    <measurement group_id="O3" value="10.8" lower_limit="8.5" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>OS in CPS ≥10 participants of the pembro combo arm was compared to OS in CPS ≥10 participants of the SOC arm to address the third primary hypothesis (superiority to SOC). The comparison was based on a Cox regression model with Efron’s method of tie handling with treatment as a covariate with stratification according to geographic region, disease status, and Fluoropyrimidine treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15804</p_value>
            <p_value_desc>One-sided p-value based on log-rank test with stratification.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ≥1 (All Participants)</title>
        <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, OS was compared separately between CPS ≥1 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
        <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
        <population>All CPS ≥1 participants in the ITT population randomized to the pembro mono arm and SOC arm were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ≥1 (All Participants)</title>
          <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, OS was compared separately between CPS ≥1 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
          <population>All CPS ≥1 participants in the ITT population randomized to the pembro mono arm and SOC arm were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="7.7" upper_limit="13.8"/>
                    <measurement group_id="O3" value="11.1" lower_limit="9.2" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>OS in CPS ≥1 participants of the pembro mono arm was compared to OS in CPS ≥1 participants of the SOC arm to address the fourth primary hypothesis (non-inferiority to SOC). The comparison was based on a Cox regression model with Efron’s method of tie handling with treatment as a covariate with stratification according to geographic region, disease status, and Fluoropyrimidine treatment.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Pre-specified non-inferiority margin: if the upper bound of the confidence interval (based on the alpha level allocated to the analysis) for the hazard ratio ([HR], pembro mono arm vs SOC) is &lt; 1.2, the pembro mono arm could be considered as non-inferior to the SOC arm in terms of OS.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>99.2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>OS in CPS ≥1 participants of the pembro mono arm was compared to OS in CPS ≥1 participants of the SOC arm to address the fifth primary hypothesis (superiority to SOC). The comparison was based on a Cox regression model with Efron’s method of tie handling with treatment as a covariate with stratification according to geographic region, disease status, and Fluoropyrimidine treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16205</p_value>
            <p_value_desc>One-sided p-value based on log-rank test with stratification.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ≥10</title>
        <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥10. Per protocol, OS was compared separately between CPS ≥10 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
        <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
        <population>All CPS ≥10 participants in the ITT population randomized to the pembro mono arm and SOC arm were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Mono vs SOC: OS in Participants With PD-L1 CPS ≥10</title>
          <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the SOC arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥10. Per protocol, OS was compared separately between CPS ≥10 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
          <population>All CPS ≥10 participants in the ITT population randomized to the pembro mono arm and SOC arm were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="9.1" upper_limit="23.1"/>
                    <measurement group_id="O3" value="10.8" lower_limit="8.5" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>OS in CPS ≥10 participants of the pembro mono arm was compared to OS in CPS ≥10 participants of the SOC arm to address the sixth primary hypothesis (superiority to SOC). The comparison was based on a Cox regression model with Efron’s method of tie handling with treatment as a covariate with stratification according to geographic region, disease status, and Fluoropyrimidine treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01491</p_value>
            <p_value_desc>One-sided p-value based on log-rank test with stratification.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pembro Combo vs SOC: Objective Response Rate (ORR) Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
        <description>ORR was defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro combo arm was compared to the SOC arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
        <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
        <population>All CPS ≥1 participants in the ITT population randomized to the pembro combo arm and SOC arm were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Combo vs SOC: Objective Response Rate (ORR) Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
          <description>ORR was defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro combo arm was compared to the SOC arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro mono arm and SOC arm and is presented later in the record.</description>
          <population>All CPS ≥1 participants in the ITT population randomized to the pembro combo arm and SOC arm were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="48.6" lower_limit="42.4" upper_limit="54.9"/>
                    <measurement group_id="O3" value="37.2" lower_limit="31.2" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ORR in CPS ≥1 participants of the pembro combo arm was compared to ORR in CPS ≥1 participants of the SOC arm based on Miettinen &amp; Nurminen method stratified by geographic region, disease status, and Fluoropyrimidine treatment.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.00447</p_value>
            <p_value_desc>No formal hypothesis testing performed; nominal p-value provided for treatment comparison.</p_value_desc>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in ORR Percentage</param_type>
            <param_value>11.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>20.0</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pembro Combo vs SOC: Duration of Response (DOR) Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
        <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 based upon BICR, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. DOR is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants) and had CR or PR. Per protocol, DOR was compared separately between CPS ≥1 responders of the pembro mono arm and SOC arm and is presented later in the record.</description>
        <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
        <population>All CPS ≥1 participants in the ITT population randomized to the pembro combo arm and SOC arm and who demonstrated a confirmed CR or PR were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Combo vs SOC: Duration of Response (DOR) Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
          <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 based upon BICR, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. DOR is reported here for all participants in the pembro combo arm and SOC arm who were PD-L1 CPS ≥1 (all participants) and had CR or PR. Per protocol, DOR was compared separately between CPS ≥1 responders of the pembro mono arm and SOC arm and is presented later in the record.</description>
          <population>All CPS ≥1 participants in the ITT population randomized to the pembro combo arm and SOC arm and who demonstrated a confirmed CR or PR were analyzed. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA=Median DOR and DOR range lower and upper limit not reached (no progressive disease by time of last disease assessment)</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA=Median DOR and DOR range lower and upper limit not reached (no progressive disease by time of last disease assessment)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pembro Mono vs SOC: ORR Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
        <description>ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro mono arm was compared to the SOC arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
        <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
        <population>All CPS ≥1 participants in the ITT population randomized to the pembro mono arm and SOC arm were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Mono vs SOC: ORR Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
          <description>ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro mono arm was compared to the SOC arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
          <population>All CPS ≥1 participants in the ITT population randomized to the pembro mono arm and SOC arm were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="10.7" upper_limit="19.8"/>
                    <measurement group_id="O3" value="37.2" lower_limit="31.2" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ORR in CPS ≥1 participants of the pembro mono arm was compared to ORR in CPS ≥1 participants of the SOC arm based on Miettinen &amp; Nurminen method stratified by geographic region, disease status, and Fluoropyrimidine treatment.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.99999</p_value>
            <p_value_desc>No formal hypothesis testing performed; nominal p-value provided for treatment comparison.</p_value_desc>
            <method>Miettinen &amp; Nurminen method</method>
            <param_type>Difference in ORR Percentage</param_type>
            <param_value>-22.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.6</ci_lower_limit>
            <ci_upper_limit>-14.9</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pembro Mono vs SOC: DOR Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
        <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 based upon BICR, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. DOR is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants) and had CR or PR. Per protocol, DOR was compared separately between CPS ≥1 responders of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
        <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
        <population>All CPS ≥1 participants in the ITT population randomized to the pembro mono arm and SOC arm and who demonstrated a confirmed CR or PR were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Mono vs SOC: DOR Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
          <description>For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 based upon BICR, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. DOR is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants) and had CR or PR. Per protocol, DOR was compared separately between CPS ≥1 responders of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
          <population>All CPS ≥1 participants in the ITT population randomized to the pembro mono arm and SOC arm and who demonstrated a confirmed CR or PR were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA=Median DOR and DOR range lower and upper limit not reached (no progressive disease by time of last disease assessment)</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA=Median DOR and DOR range lower and upper limit not reached (no progressive disease by time of last disease assessment)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pembro Mono vs SOC: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
        <description>PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.
Per protocol, PFS in the pembro mono arm was compared to the SOC arm as a pre-specified secondary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
        <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
        <population>All CPS ≥1 participants in the ITT population randomized to the pembro mono arm and SOC arm were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Mono vs SOC: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (All Participants)</title>
          <description>PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.
Per protocol, PFS in the pembro mono arm was compared to the SOC arm as a pre-specified secondary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and SOC arm who were PD-L1 CPS ≥1 (all participants). Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro combo arm and SOC arm and is presented earlier in the record.</description>
          <population>All CPS ≥1 participants in the ITT population randomized to the pembro mono arm and SOC arm were analyzed. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.5" upper_limit="2.8"/>
                    <measurement group_id="O3" value="6.4" lower_limit="5.7" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PFS in CPS ≥1 participants of the pembro mono arm was compared to PFS in CPS ≥1 participants of the SOC arm based on a Cox regression model with Efron’s method of tie handling with treatment as a covariate with stratification according to geographic region, disease status, and fluoropyrimidine treatment.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.00000</p_value>
            <p_value_desc>No formal hypothesis testing performed; nominal p-value provided for treatment comparison.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pembro Mono vs SOC: Change From Baseline to Week 18 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score</title>
        <description>The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question &quot;How would you rate your overall health during the past week?&quot; (Item 29) and the Quality of Life (QoL) question &quot;How would you rate your overall quality of life during the past week?&quot; (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared between all participants of the pembro mono arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared separately between all participants of the pembro combo arm and SOC arm and is presented later in the record.</description>
        <time_frame>Baseline, Week 18</time_frame>
        <population>Participants in the pembro mono arm and SOC arm who received ≥1 dose of study drug and who had EORTC-QLQ-C30 assessments available at baseline or post-baseline up to Week 18. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Mono vs SOC: Change From Baseline to Week 18 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score</title>
          <description>The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question &quot;How would you rate your overall health during the past week?&quot; (Item 29) and the Quality of Life (QoL) question &quot;How would you rate your overall quality of life during the past week?&quot; (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared between all participants of the pembro mono arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared separately between all participants of the pembro combo arm and SOC arm and is presented later in the record.</description>
          <population>Participants in the pembro mono arm and SOC arm who received ≥1 dose of study drug and who had EORTC-QLQ-C30 assessments available at baseline or post-baseline up to Week 18. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" lower_limit="-5.81" upper_limit="1.98"/>
                    <measurement group_id="O3" value="-1.75" lower_limit="-5.17" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 18 in EORTC-QLQ-C30 GHS/QoL combined score was compared between all participants of the pembro mono arm and the SOC arm. Comparison based on constrained longitudinal data analysis (cLDA) model with GHS/QoL score as response variable and treatment by visit interaction and stratification factors (geographic region, disease status, and fluoropyrimidine treatment) as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.948</p_value>
            <p_value_desc>No formal hypothesis testing performed; nominal p-value provided for treatment comparison.</p_value_desc>
            <method>cLDA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.01</ci_lower_limit>
            <ci_upper_limit>4.69</ci_upper_limit>
            <estimate_desc>Stratified analyses could be based on collapsing strata with insufficient number of participants or events; strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pembro Combo vs SOC: Change From Baseline to Week 18 in the EORTC QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Combined Score</title>
        <description>The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the GHS question &quot;How would you rate your overall health during the past week?&quot; (Item 29) and the QoL question &quot;How would you rate your overall quality of life during the past week?&quot; (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared between all participants of the pembro combo arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared separately between all participants of the pembro mono arm and SOC arm and is presented earlier in the record.</description>
        <time_frame>Baseline, Week 18</time_frame>
        <population>Participants in the pembro combo arm and SOC arm who received ≥1 dose of study drug and who had EORTC-QLQ-C30 assessments available at baseline or post-baseline up to Week 18. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Combo vs SOC: Change From Baseline to Week 18 in the EORTC QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Combined Score</title>
          <description>The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the GHS question &quot;How would you rate your overall health during the past week?&quot; (Item 29) and the QoL question &quot;How would you rate your overall quality of life during the past week?&quot; (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared between all participants of the pembro combo arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the GHS/QoL combined score was compared separately between all participants of the pembro mono arm and SOC arm and is presented earlier in the record.</description>
          <population>Participants in the pembro combo arm and SOC arm who received ≥1 dose of study drug and who had EORTC-QLQ-C30 assessments available at baseline or post-baseline up to Week 18. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-0.09" lower_limit="-3.36" upper_limit="3.19"/>
                    <measurement group_id="O3" value="-2.07" lower_limit="-5.43" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 18 in EORTC-QLQ-C30 GHS/QoL combined score was compared between all participants of the pembro combo arm and the SOC arm. Comparison based on cLDA model with GHS/QoL score as response variable and treatment by visit interaction and stratification factors (geographic region, disease status, and fluoropyrimidine treatment) as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.368</p_value>
            <p_value_desc>No formal hypothesis testing performed; nominal p-value provided for treatment comparison.</p_value_desc>
            <method>cLDA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>1.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.34</ci_lower_limit>
            <ci_upper_limit>6.31</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pembro Mono vs. SOC: Change From Baseline to Week 18 in EORTC QLQ-Module for Gastric Cancer (STO22) Pain Symptom Subscale Score</title>
        <description>EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales that assess dysphagia (3 items), dietary restriction (4 items), pain (4 items), upper gastro-esophageal symptoms (3 items), and emotional problems (3 items), and questions on dry mouth, taste, body image, and hair loss. Participant responses to the Pain symptom subscale (Items 34-37) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. Per protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared between the pembro mono arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared separately between the pembro combo arm and SOC arm and is presented later in the record.</description>
        <time_frame>Baseline, Week 18</time_frame>
        <population>Participants in the pembro mono arm and SOC arm who received ≥1 dose of study drug and who had EORTC-QLQ-STO22 assessments available at baseline or post-baseline up to Week 18. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Mono vs. SOC: Change From Baseline to Week 18 in EORTC QLQ-Module for Gastric Cancer (STO22) Pain Symptom Subscale Score</title>
          <description>EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales that assess dysphagia (3 items), dietary restriction (4 items), pain (4 items), upper gastro-esophageal symptoms (3 items), and emotional problems (3 items), and questions on dry mouth, taste, body image, and hair loss. Participant responses to the Pain symptom subscale (Items 34-37) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. Per protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared between the pembro mono arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared separately between the pembro combo arm and SOC arm and is presented later in the record.</description>
          <population>Participants in the pembro mono arm and SOC arm who received ≥1 dose of study drug and who had EORTC-QLQ-STO22 assessments available at baseline or post-baseline up to Week 18. Per protocol, the pembro combo arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" lower_limit="-4.67" upper_limit="2.39"/>
                    <measurement group_id="O3" value="-3.49" lower_limit="-6.60" upper_limit="-0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 18 in EORTC-QLQ-STO22 Pain symptom subscale score was compared between all participants of the pembro mono arm and the SOC arm. Comparison based on cLDA model with GHS/QoL score as response variable and treatment by visit interaction and stratification factors (geographic region, disease status, and fluoropyrimidine treatment) as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <p_value_desc>No formal hypothesis testing performed; nominal p-value provided for treatment comparison.</p_value_desc>
            <method>cLDA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>6.89</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pembro Combo vs. SOC: Change From Baseline to Week 18 in EORTC QLQ-STO22 Pain Symptom Subscale Score</title>
        <description>EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales that assess dysphagia (3 items), dietary restriction (4 items), pain (4 items), upper gastro-esophageal symptoms (3 items), and emotional problems (3 items), and questions on dry mouth, taste, body image, and hair loss. Participant responses to the Pain symptom subscale (Items 34-37) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. Per protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared between the pembro combo arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared separately between the pembro mono arm and SOC arm and is presented earlier in the record.</description>
        <time_frame>Baseline, Week 18</time_frame>
        <population>Participants in the pembro combo arm and SOC arm who received ≥1 dose of study drug and who had EORTC-QLQ-STO22 assessments available at baseline or post-baseline up to Week 18. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pembro Combo vs. SOC: Change From Baseline to Week 18 in EORTC QLQ-STO22 Pain Symptom Subscale Score</title>
          <description>EORTC-QLQ-STO22 is a 22-item questionnaire developed to assess QoL of gastric cancer participants. It consists of 5 multi-item subscales that assess dysphagia (3 items), dietary restriction (4 items), pain (4 items), upper gastro-esophageal symptoms (3 items), and emotional problems (3 items), and questions on dry mouth, taste, body image, and hair loss. Participant responses to the Pain symptom subscale (Items 34-37) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. Per protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared between the pembro combo arm and the SOC arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 18 in the EORTC-QLQ-STO22 Pain score was compared separately between the pembro mono arm and SOC arm and is presented earlier in the record.</description>
          <population>Participants in the pembro combo arm and SOC arm who received ≥1 dose of study drug and who had EORTC-QLQ-STO22 assessments available at baseline or post-baseline up to Week 18. Per protocol, the pembro mono arm was compared to the SOC arm separately and not included in this analysis.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-10.12" lower_limit="-13.08" upper_limit="-7.17"/>
                    <measurement group_id="O3" value="-3.56" lower_limit="-6.61" upper_limit="-0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Week 18 in EORTC-QLQ-STO22 Pain symptom subscale score was compared between all participants of the pembro combo arm and the SOC arm. Comparison based on cLDA model with GHS/QoL score as response variable and treatment by visit interaction and stratification factors (geographic region, disease status, and fluoropyrimidine treatment) as covariates.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>No formal hypothesis testing performed; nominal p-value provided for treatment comparison.</p_value_desc>
            <method>cLDA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-6.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.55</ci_lower_limit>
            <ci_upper_limit>-2.58</ci_upper_limit>
            <estimate_desc>Since stratified analyses could be based on collapsing strata with insufficient number of participants or events, strata were pooled in some cases based on clinical judgement and actual counts.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing an Adverse Event (AE)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an adverse event. The number of participants who experienced an AE was reported for each arm according to the treatment received.</description>
        <time_frame>Up to approximately 31.5 months</time_frame>
        <population>All randomized participants who received at least 1 dose of trial treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event (AE)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an adverse event. The number of participants who experienced an AE was reported for each arm according to the treatment received.</description>
          <population>All randomized participants who received at least 1 dose of trial treatment were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="244"/>
                    <measurement group_id="O3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Discontinuing Study Treatment Due to an AE</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an adverse event. The number of participants who discontinued study treatment due to an AE was reported for each arm according to the treatment received.</description>
        <time_frame>Up to approximately 28.5 months</time_frame>
        <population>All randomized participants who received at least 1 dose of trial treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
            <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
          </group>
          <group group_id="O2">
            <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
            <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + SOC Chemotherapy (SOC)</title>
            <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Study Treatment Due to an AE</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an adverse event. The number of participants who discontinued study treatment due to an AE was reported for each arm according to the treatment received.</description>
          <population>All randomized participants who received at least 1 dose of trial treatment were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 42 months (through Final Analysis cut-off date of 26-Mar-2019)</time_frame>
      <desc>All-Cause Mortality reported for all randomized participants.
Serious AEs and Other AEs were reported for all randomized participants who received at least 1 dose of study treatment. Per protocol, disease progression of cancer on study was not considered an AE unless considered related to study drug. Therefore, MedDRA preferred terms &quot;Neoplasm progression&quot;, &quot;Malignant neoplasm progression&quot; and &quot;Disease progression&quot; not related to study drug are excluded as AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pembrolizumab Monotherapy (Pembro Mono)</title>
          <description>Participants received pembrolizumab 200 mg IV Q3W.</description>
        </group>
        <group group_id="E2">
          <title>Pembrolizumab + SOC Chemotherapy (Pembro Combo)</title>
          <description>Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
        </group>
        <group group_id="E3">
          <title>Placebo + SOC Chemotherapy (SOC)</title>
          <description>Participants received placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="216" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="250"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="250"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Incarcerated hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Peritoneocutaneous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Immune-mediated hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vascular device infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Refeeding syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oncologic complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Autoimmune nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="233" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="61" subjects_at_risk="254"/>
                <counts group_id="E2" events="149" subjects_affected="112" subjects_at_risk="250"/>
                <counts group_id="E3" events="142" subjects_affected="107" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="52" subjects_affected="21" subjects_at_risk="250"/>
                <counts group_id="E3" events="51" subjects_affected="26" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="201" subjects_affected="95" subjects_at_risk="250"/>
                <counts group_id="E3" events="222" subjects_affected="102" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="38" subjects_affected="27" subjects_at_risk="250"/>
                <counts group_id="E3" events="33" subjects_affected="26" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="250"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="254"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="250"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="254"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="56" subjects_affected="46" subjects_at_risk="254"/>
                <counts group_id="E2" events="50" subjects_affected="42" subjects_at_risk="250"/>
                <counts group_id="E3" events="54" subjects_affected="41" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="254"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="250"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="43" subjects_affected="36" subjects_at_risk="254"/>
                <counts group_id="E2" events="108" subjects_affected="71" subjects_at_risk="250"/>
                <counts group_id="E3" events="83" subjects_affected="68" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="60" subjects_affected="35" subjects_at_risk="254"/>
                <counts group_id="E2" events="153" subjects_affected="83" subjects_at_risk="250"/>
                <counts group_id="E3" events="106" subjects_affected="71" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="254"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="250"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="254"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="59" subjects_affected="49" subjects_at_risk="254"/>
                <counts group_id="E2" events="295" subjects_affected="162" subjects_at_risk="250"/>
                <counts group_id="E3" events="236" subjects_affected="129" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E2" events="49" subjects_affected="33" subjects_at_risk="250"/>
                <counts group_id="E3" events="39" subjects_affected="35" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="64" subjects_affected="49" subjects_at_risk="254"/>
                <counts group_id="E2" events="148" subjects_affected="84" subjects_at_risk="250"/>
                <counts group_id="E3" events="142" subjects_affected="79" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="254"/>
                <counts group_id="E2" events="53" subjects_affected="41" subjects_at_risk="250"/>
                <counts group_id="E3" events="81" subjects_affected="47" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="63" subjects_affected="49" subjects_at_risk="254"/>
                <counts group_id="E2" events="156" subjects_affected="105" subjects_at_risk="250"/>
                <counts group_id="E3" events="112" subjects_affected="75" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="57" subjects_affected="41" subjects_at_risk="250"/>
                <counts group_id="E3" events="62" subjects_affected="34" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="254"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="254"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="250"/>
                <counts group_id="E3" events="26" subjects_affected="25" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="254"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="254"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="254"/>
                <counts group_id="E2" events="52" subjects_affected="30" subjects_at_risk="250"/>
                <counts group_id="E3" events="58" subjects_affected="34" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" events="119" subjects_affected="59" subjects_at_risk="250"/>
                <counts group_id="E3" events="79" subjects_affected="40" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="38" subjects_affected="23" subjects_at_risk="250"/>
                <counts group_id="E3" events="21" subjects_affected="17" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="254"/>
                <counts group_id="E2" events="63" subjects_affected="54" subjects_at_risk="250"/>
                <counts group_id="E3" events="33" subjects_affected="33" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" events="71" subjects_affected="30" subjects_at_risk="250"/>
                <counts group_id="E3" events="52" subjects_affected="25" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="53" subjects_affected="48" subjects_at_risk="254"/>
                <counts group_id="E2" events="134" subjects_affected="93" subjects_at_risk="250"/>
                <counts group_id="E3" events="127" subjects_affected="90" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="254"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="254"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E3" events="28" subjects_affected="23" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="254"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E2" events="49" subjects_affected="35" subjects_at_risk="250"/>
                <counts group_id="E3" events="62" subjects_affected="42" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="43" subjects_affected="34" subjects_at_risk="250"/>
                <counts group_id="E3" events="48" subjects_affected="32" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="254"/>
                <counts group_id="E2" events="21" subjects_affected="12" subjects_at_risk="250"/>
                <counts group_id="E3" events="26" subjects_affected="20" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="250"/>
                <counts group_id="E3" events="15" subjects_affected="9" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="254"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="254"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="254"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="250"/>
                <counts group_id="E3" events="22" subjects_affected="15" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="250"/>
                <counts group_id="E3" events="29" subjects_affected="26" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="254"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="250"/>
                <counts group_id="E3" events="22" subjects_affected="16" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="36" subjects_affected="31" subjects_at_risk="250"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="250"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="254"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="250"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="254"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="250"/>
                <counts group_id="E3" events="26" subjects_affected="23" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="250"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E3" events="21" subjects_affected="12" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="250"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="250"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="69" subjects_affected="60" subjects_at_risk="250"/>
                <counts group_id="E3" events="57" subjects_affected="46" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="254"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="250"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="254"/>
                <counts group_id="E2" events="39" subjects_affected="30" subjects_at_risk="250"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

